Current and historical daily PE Ratio for NetraMark Holdings Inc (
XCNQ:AIAI
) from 2021 to Jun 06 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. NetraMark stock (XCNQ:AIAI) PE ratio as of Jun 06 2024 is 0.
More Details
NetraMark Holdings Inc (XCNQ:AIAI) PE Ratio (TTM) Chart
NetraMark Holdings Inc (XCNQ:AIAI) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 770
- 1
- 2
- 3
- 4
- 5
- 6
- 9
| NetraMark PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-06 | At Loss | 2024-04-03 | At Loss |
| 2024-06-05 | At Loss | 2024-04-02 | At Loss |
| 2024-06-04 | At Loss | 2024-04-01 | At Loss |
| 2024-06-03 | At Loss | 2024-03-28 | At Loss |
| 2024-05-31 | At Loss | 2024-03-27 | At Loss |
| 2024-05-30 | At Loss | 2024-03-26 | At Loss |
| 2024-05-29 | At Loss | 2024-03-25 | At Loss |
| 2024-05-28 | At Loss | 2024-03-22 | At Loss |
| 2024-05-27 | At Loss | 2024-03-21 | At Loss |
| 2024-05-24 | At Loss | 2024-03-20 | At Loss |
| 2024-05-23 | At Loss | 2024-03-19 | At Loss |
| 2024-05-22 | At Loss | 2024-03-18 | At Loss |
| 2024-05-21 | At Loss | 2024-03-15 | At Loss |
| 2024-05-17 | At Loss | 2024-03-14 | At Loss |
| 2024-05-16 | At Loss | 2024-03-13 | At Loss |
| 2024-05-15 | At Loss | 2024-03-12 | At Loss |
| 2024-05-14 | At Loss | 2024-03-11 | At Loss |
| 2024-05-13 | At Loss | 2024-03-08 | At Loss |
| 2024-05-10 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
NetraMark Holdings Inc (XCNQ:AIAI) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
NetraMark Holdings Inc
NAICS : 923120
SIC : 8699
ISIN : CA64119M1059
Share Class Description:
XCNQ:AIAI: Ordinary SharesDescription
NetraMark Holdings Inc is focused on the application of an Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers